Acrivon debuts with Lilly DDR inhibitor to test proteomics-based companion diagnostics platform

Acrivon launched with a platform for designing proteomics-based companion diagnostics, and a targeted therapy licensed from Eli Lilly and Co. (NYSE:LLY) will become its first test case.

Though most companion diagnostics are based on genomic profiles, Acrivon Therapeutics Inc.’s precision oncology platform centers on protein markers. The company’s Acrivon Predictive Precision Proteomics (AP3) platform was developed by co-founder and CEO Peter Blume-Jensen to match the company’s therapies with patients who may benefit...